Angios Biotech

Executive Summary

Angios Biotech is an Austrian biotechnology company leveraging its patented induced pluripotent stem cell (iPSC) technology to develop human blood vessel organoids for research, drug discovery, and regenerative medicine. The company focuses on diabetic vasculopathies, vascular transplants, and animal-free drug screening platforms. Its organoid platform offers a physiologically relevant human model for vascular diseases, potentially reducing reliance on animal testing and improving translational outcomes. Currently at the pre-clinical stage, Angios is building a pipeline of cell-based therapies targeting major unmet needs in vascular health. The company's proprietary technology enables the generation of patient-specific vascular organoids, which could accelerate drug development and enable personalized medicine approaches. With a strong intellectual property position and a clear focus on high-value indications, Angios Biotech is well-positioned to attract partnerships and funding to advance its platform toward clinical validation. The company's unique approach to vascular disease modeling could disrupt traditional drug discovery paradigms and open new avenues for regenerative therapies.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data in diabetic vasculopathy70% success
• Q4 2026Pharmaceutical partnership for drug screening platform50% success
• Q1 2027Series A financing round60% success